Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4) Authors: Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y PMID: 25655053 [PubMed - indexed for MEDLINE]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research

Related Links:

by Lauren A. Castro, Trevor Bedford, Lauren Ancel Meyers Influenza A/H3N2 is a rapidly evolving virus which experiences major antigenic transitions every two to eight years. Anticipating the timing and outcome of transitions is critical to developing effective seasonal influenza vaccines. Using a published phylodynamic model of influenza transmission, w e identified indicators of future evolutionary success for an emerging antigenic cluster and quantified fundamental trade-offs in our ability to make such predictions. The eventual fate of a new cluster depends on its initial epidemiological growth rate––which ...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
Why are some people better able to fight off the flu than others? Part of the answer, according to a new study, is related to the first flu strain we encounter in childhood.Scientists from UCLA and the University of Arizona have found that people ’s ability to fight off the flu virus is determined not only by the subtypes of flu they have had throughout their lives, but also by the sequence in which they are been infected by the viruses. Their study is published in the open-access journal PLoS Pathogens.The research offers an explanation for why some people fare much worse than others when infected with the...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSION: Our results confirm the public health benefits from seasonal influenza vaccination, despite the suboptimal effectiveness against A(H3N2) strains. Continued monitoring of VE is essential, and routinely collected surveillance data can be valuable in this regard. PMID: 32033848 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
CONCLUSION: These results suggest moderate effectiveness of influenza vaccination against A(H1N1)pdm09 and low effectiveness against A(H3N2) influenza in the 2018-2019 season. Vaccination in prior seasons maintained a notable protective effect. Strains included in previous vaccines were as effective as the current vaccine strain, and both added their effects against influenza A(H1N1)pdm09. PMID: 31982263 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Flu season is always unpredictable. Different viral strains circulate each year, which makes forecasting the disease’s spread—and formulating the annual flu vaccine—an educated guessing game. Even so, the 2019-2020 flu season has been particularly unusual. Influenza B, the viral strain that usually circulates toward the end of flu season, instead emerged first this year, shifting usual transmission patterns. A vaccine mismatch and reduced immunity to influenza B may have contributed to the early and severe start of this flu season. What does that mean for the months ahead? TIME asked Lynnette Brammer, an ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
(CNN) — This year’s flu vaccine is “not a very good match” for a common strain of the flu that’s especially tough on children, according to the nation’s top infectious disease doctor. “It’s not a very good match for B/Victoria,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, referring to the strain. “It’s not an awful match, but it’s not a very good match.” Children are particularly susceptible to influenza B/Victoria. Fauci said even though the match for B/Victoria isn’t great, a flu shot can...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston CNN Flu Vaccine Source Type: news
CONCLUSIONS: The immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TIV. PMID: 31948819 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Canada's national influenza season started in week 47 between November 17 to 23, 2019. Of the 3,762 laboratory-confirmed influenza detections reported from August 25 to December 14, 2019, 61% were influenza A, and of those subtyped, 68% were A(H3N2). Influenza B detections are above average for this time of year. Indicators of influenza activity are within the expected range for this time of year. The majority of hospitalizations reported by provinces and territories have been associated with influenza A(H3N2) (76%), and the greatest proportion have been among adults 65 years and older (40%). Among sentin...
Source: Can Commun Dis Rep - Category: Infectious Diseases Authors: Tags: Can Commun Dis Rep Source Type: research
Publication date: 24 December 2019Source: Cell Reports, Volume 29, Issue 13Author(s): Seth J. Zost, Juhye Lee, Megan E. Gumina, Kaela Parkhouse, Carole Henry, Nicholas C. Wu, Chang-Chun D. Lee, Ian A. Wilson, Patrick C. Wilson, Jesse D. Bloom, Scott E. HensleySummaryAntibodies targeting the receptor binding site (RBS) of the influenza virus hemagglutinin (HA) protein are usually not broadly reactive because their footprints are typically large and extend to nearby variable HA residues. Here, we identify several human H3N2 HA RBS-targeting monoclonal antibodies (mAbs) that are sensitive to substitutions in conventional anti...
Source: Cell Reports - Category: Cytology Source Type: research
CONCLUSION: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age. CLINICAL TRIAL REGISTRATION: NCT03336593. PMID: 31862195 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: H3N2 | Infectious Diseases | Influenza | Influenza Vaccine | Vaccines